Compare EKSO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | XLO |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 39.4M |
| IPO Year | 2012 | 2021 |
| Metric | EKSO | XLO |
|---|---|---|
| Price | $10.40 | $7.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.50 | ★ $28.00 |
| AVG Volume (30 Days) | 88.5K | ★ 315.0K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.76 | ★ 60.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | $81.23 | $626.78 |
| Revenue Next Year | $7.29 | $79.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.46 |
| 52 Week High | $13.50 | $8.09 |
| Indicator | EKSO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 91.60 |
| Support Level | $9.18 | $0.63 |
| Resistance Level | $10.76 | N/A |
| Average True Range (ATR) | 1.01 | 0.29 |
| MACD | -0.22 | 0.83 |
| Stochastic Oscillator | 12.79 | 95.81 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.